|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:TYK2-SHC2 (FusionGDB2 ID:94995) |
Fusion Gene Summary for TYK2-SHC2 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TYK2-SHC2 | Fusion gene ID: 94995 | Hgene | Tgene | Gene symbol | TYK2 | SHC2 | Gene ID | 7297 | 25759 |
| Gene name | tyrosine kinase 2 | SHC adaptor protein 2 | |
| Synonyms | IMD35|JTK1 | SCK|SHCB|SLI | |
| Cytomap | 19p13.2 | 19p13.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | non-receptor tyrosine-protein kinase TYK2 | SHC-transforming protein 2SH2 domain protein C2SHC (Src homology 2 domain containing) transforming protein 2SHC-transforming protein Bneuronal Shc adaptor homologprotein Scksrc homology 2 domain-containing-transforming protein C2 | |
| Modification date | 20200329 | 20200313 | |
| UniProtAcc | . | . | |
| Ensembl transtripts involved in fusion gene | ENST00000264818, ENST00000524462, ENST00000525621, ENST00000529370, ENST00000529422, | ENST00000264554, | |
| Fusion gene scores | * DoF score | 13 X 11 X 8=1144 | 7 X 4 X 7=196 |
| # samples | 15 | 7 | |
| ** MAII score | log2(15/1144*10)=-2.93105264628251 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/196*10)=-1.48542682717024 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: TYK2 [Title/Abstract] AND SHC2 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | TYK2(10468440)-SHC2(430747), # samples:3 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene breakpoints across TYK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across SHC2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | BRCA | TCGA-BH-A0BP-01A | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| ChimerDB4 | BRCA | TCGA-BH-A0BP-01A | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| ChimerDB4 | BRCA | TCGA-BH-A0BP-01A | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
Top |
Fusion Gene ORF analysis for TYK2-SHC2 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000264818 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| In-frame | ENST00000524462 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| In-frame | ENST00000525621 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| intron-3CDS | ENST00000529370 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| intron-3CDS | ENST00000529422 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000264818 | TYK2 | chr19 | 10468440 | - | ENST00000264554 | SHC2 | chr19 | 430747 | - | 3850 | 2466 | 0 | 3104 | 1034 |
| ENST00000524462 | TYK2 | chr19 | 10468440 | - | ENST00000264554 | SHC2 | chr19 | 430747 | - | 3441 | 2057 | 38 | 2695 | 885 |
| ENST00000525621 | TYK2 | chr19 | 10468440 | - | ENST00000264554 | SHC2 | chr19 | 430747 | - | 4332 | 2948 | 482 | 3586 | 1034 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000264818 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - | 0.008404858 | 0.9915951 |
| ENST00000524462 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - | 0.01880479 | 0.9811952 |
| ENST00000525621 | ENST00000264554 | TYK2 | chr19 | 10468440 | - | SHC2 | chr19 | 430747 | - | 0.012428637 | 0.98757136 |
Top |
Fusion Genomic Features for TYK2-SHC2 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for TYK2-SHC2 |
| Go to FGviewer for the breakpoints of chr19:10468440-chr19:430747 - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | . |
| FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. | FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000264818 | - | 15 | 23 | 26_431 | 822.0 | 1188.0 | Domain | FERM |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000264818 | - | 15 | 23 | 450_529 | 822.0 | 1188.0 | Domain | Note=SH2%3B atypical |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000525621 | - | 17 | 25 | 26_431 | 822.0 | 1188.0 | Domain | FERM |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000525621 | - | 17 | 25 | 450_529 | 822.0 | 1188.0 | Domain | Note=SH2%3B atypical |
| Tgene | SHC2 | chr19:10468440 | chr19:430747 | ENST00000264554 | 7 | 13 | 487_578 | 370.0 | 694.6666666666666 | Domain | SH2 |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000264818 | - | 15 | 23 | 589_875 | 822.0 | 1188.0 | Domain | Protein kinase 1 |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000264818 | - | 15 | 23 | 897_1176 | 822.0 | 1188.0 | Domain | Protein kinase 2 |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000525621 | - | 17 | 25 | 589_875 | 822.0 | 1188.0 | Domain | Protein kinase 1 |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000525621 | - | 17 | 25 | 897_1176 | 822.0 | 1188.0 | Domain | Protein kinase 2 |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000264818 | - | 15 | 23 | 903_911 | 822.0 | 1188.0 | Nucleotide binding | ATP |
| Hgene | TYK2 | chr19:10468440 | chr19:430747 | ENST00000525621 | - | 17 | 25 | 903_911 | 822.0 | 1188.0 | Nucleotide binding | ATP |
| Tgene | SHC2 | chr19:10468440 | chr19:430747 | ENST00000264554 | 7 | 13 | 147_329 | 370.0 | 694.6666666666666 | Domain | PID | |
| Tgene | SHC2 | chr19:10468440 | chr19:430747 | ENST00000264554 | 7 | 13 | 330_486 | 370.0 | 694.6666666666666 | Region | Note=CH1 |
Top |
Fusion Gene Sequence for TYK2-SHC2 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >In-frame_ENST00000264818_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(transcript)=3850nt_BP=2466nt ATGCCTCTGCGCCACTGGGGGATGGCCAGGGGCAGTAAGCCCGTTGGGGATGGAGCCCAGCCCATGGCTGCCATGGGAGGCCTGAAGGTG CTTCTGCACTGGGCTGGTCCAGGCGGCGGGGAGCCCTGGGTCACTTTCAGTGAGTCATCGCTGACAGCTGAGGAAGTCTGCATCCACATT GCACATAAAGTTGGTATCACTCCTCCTTGCTTCAATCTCTTTGCCCTCTTCGATGCTCAGGCCCAAGTCTGGTTGCCCCCAAACCACATC CTAGAGATCCCCAGAGATGCAAGCCTGATGCTATATTTCCGCATAAGGTTTTATTTCCGGAACTGGCATGGCATGAATCCTCGGGAACCG GCTGTGTACCGTTGTGGGCCCCCAGGAACCGAGGCATCCTCAGATCAGACAGCACAGGGGATGCAACTCCTGGACCCAGCCTCATTTGAG TACCTCTTTGAGCAGGGCAAGCATGAGTTTGTGAATGACGTGGCATCACTGTGGGAGCTGTCGACCGAGGAGGAGATCCACCACTTTAAG AATGAGAGCCTGGGCATGGCCTTTCTGCACCTCTGTCACCTCGCTCTCCGCCATGGCATCCCCCTGGAGGAGGTGGCCAAGAAGACCAGC TTCAAGGACTGCATCCCGCGCTCCTTCCGCCGGCATATCCGGCAGCACAGCGCCCTGACCCGGCTGCGCCTTCGGAACGTCTTCCGCAGG TTCCTGCGGGACTTCCAGCCGGGCCGACTCTCCCAGCAGATGGTCATGGTCAAATACCTAGCCACACTCGAGCGGCTGGCACCCCGCTTC GGCACAGAGCGTGTGCCCGTGTGCCACCTGAGGCTGCTGGCCCAGGCCGAGGGGGAGCCCTGCTACATCCGGGACAGTGGGGTGGCCCCT ACAGACCCTGGCCCTGAGTCTGCTGCTGGGCCCCCAACCCACGAGGTGCTGGTGACAGGCACTGGTGGCATCCAGTGGTGGCCAGTAGAG GAGGAGGTGAACAAGGAGGAGGGTTCTAGTGGCAGCAGTGGCAGGAACCCCCAAGCCAGCCTGTTTGGGAAGAAGGCCAAGGCTCACAAG GCAGTCGGCCAGCCGGCAGACAGGCCGCGGGAGCCACTGTGGGCCTACTTCTGTGACTTCCGGGACATCACCCACGTGGTGCTGAAAGAG CACTGTGTCAGCATCCACCGGCAGGACAACAAGTGCCTGGAGCTGAGCTTGCCTTCCCGGGCTGCGGCGCTGTCCTTCGTGTCGCTGGTG GACGGCTATTTCCGCCTGACGGCCGACTCCAGCCACTACCTGTGCCACGAGGTGGCTCCCCCACGGCTGGTGATGAGCATCCGGGATGGG ATCCACGGACCCCTGCTGGAGCCATTTGTGCAGGCCAAGCTGCGGCCCGAGGACGGCCTGTACCTCATTCACTGGAGCACCAGCCACCCC TACCGCCTGATCCTCACAGTGGCCCAGCGTAGCCAGGCACCAGACGGCATGCAGAGCTTGCGGCTCCGAAAGTTCCCCATTGAGCAGCAG GACGGGGCCTTCGTGCTGGAGGGCTGGGGCCGGTCCTTCCCCAGCGTTCGGGAACTTGGGGCTGCCTTGCAGGGCTGCTTGCTGAGGGCC GGGGATGACTGCTTCTCTCTGCGTCGCTGTTGCCTGCCCCAACCAGGAGAAACCTCCAATCTCATCATCATGCGGGGGGCTCGGGCCAGC CCCAGGACACTCAACCTCAGCCAGCTCAGCTTCCACCGGGTTGACCAGAAGGAGATCACCCAGCTGTCCCACTTGGGCCAGGGCACAAGG ACCAACGTGTATGAGGGCCGCCTGCGAGTGGAGGGCAGCGGGGACCCTGAGGAGGGCAAGATGGATGACGAGGACCCCCTCGTGCCTGGC AGGGACCGTGGGCAGGAGCTACGAGTGGTGCTCAAAGTGCTGGACCCTAGTCACCATGACATCGCCCTGGCCTTCTACGAGACAGCCAGC CTCATGAGCCAGGTCTCCCACACGCACCTGGCCTTCGTGCATGGCGTCTGTGTGCGCGGCCCTGAAAATATCATGGTGACAGAGTACGTG GAGCACGGACCCCTGGATGTGTGGCTGCGGAGGGAGCGGGGCCATGTGCCCATGGCTTGGAAGATGGTGGTGGCCCAGCAGCTGGCCAGC GCCCTCAGCTACCTGGAGAACAAGAACCTGGTTCATGGTAATGTGTGTGGCCGGAACATCCTGCTGGCCCGGCTGGGGTTGGCAGAGGGC ACCAGCCCCTTCATCAAGCTGAGTGATCCTGGCGTGGGCCTGGGCGCCCTCTCCAGGGAGGAGCGGGTGGAGAGGATCCCCTGGCTGGCC CCCGAATGCCTACCAGGTGGGGCCAACAGCCTAAGCACCGCCATGGACAAGTGGGGGTTTGGCGCCACCCTCCTGGAGATCTGCTTTGAC GGAGAGGCCCCTCTGCAGAGCCGCAGTCCCTCCGAGGGCCCATCTCCTTCTCTAAGAGATGCCTGCAGCCTGCCATGGGACGTGGGGTCC ACCGGTACAGCTCCACCGGGGGACGGCTACGTGCAGGCGGACGCCCGGGGCCCCCCGGACCACGAGGAGCACCTGTATGTCAACACCCAG GGTCTGGACGCCCCCGAGCCGGAGGACAGCCCCAAAAAGGATCTGTTTGACATGCGACCCTTTGAGGATGCCCTGAAGTTGCATGAGTGC TCAGTGGCGGCAGGCGTGACAGCAGCCCCTCTTCCCTTGGAGGACCAGTGGCCCAGCCCCCCTACCCGCCGGGCCCCTGTGGCCCCCACG GAGGAACAGCTGCGTCAGGAGCCCTGGTACCACGGCCGGATGAGCCGCCGGGCGGCAGAGAGGATGCTTCGAGCTGACGGGGACTTCCTT GTGCGAGACAGCGTCACCAACCCCGGGCAGTATGTCCTCACCGGCATGCACGCCGGGCAGCCCAAGCACCTGCTGCTCGTGGACCCCGAG GGCGTGGTACGGACGAAGGACGTGCTGTTTGAGAGCATCAGCCACCTGATCGACCACCACCTGCAGAACGGGCAGCCCATCGTGGCCGCC GAGAGTGAGCTGCACCTGCGTGGCGTGGTCTCACGGGAGCCCTGAGCCAGGTGACCGTTCTCAGCCCTGGCTCCTGCCTGTTCTCAGCCC CGGCTCCTGCCTGTCATGGCCTTGGGGCTCTCAGCCCTCCTCCTGGATCCTGGTCAGGCCGAACCACCGCTGCCTCTCCTTCCTCCGCAT GAGCCTCTGGCATGGTCCTTCCTCCAGCTGGCCCCGGGCTGGGCAGAGCCTCCTCCTGCCGGGGCCCCTGCCCACCCCCTCCTTTGCCTG GAGTGAGGGTGTTCATACCAAAGACGGAACCATTTCGCCTTTAAAGAAAATATATCCAGAAGCAGCCGCTGCCTCGGAGCCCTGGCCCTT GGGTCCCCCTCTCGCCTGGCTGGTTCGGTCTAACGCCCCGGAGAGTCAGGGCTCCCAGGACCCTGGGGAGGAGGCGGATTCCGGGCCTGG CTGGGCTTCCTCTTCCCACCTGAGGACTGGGTGCACAGTTGTCTTTGAGGGGGGACGCTTAAGGTGCTTTGGGGTTCTCAGGCCAGGATA CATGCTGGCGCTGAAGTGCAGGCAGCCTTGAGGTCACCTGGGATCTCGGGGTAGCCAGGCTGCTCCAAGACAGTGGATATCGAGGCAGTC GTGAGGCCCCTACTCCACCTGGGAGCAGGGGAAGGACGTGGTTGCCTGGCCTGGGCTGCGCCCAGCAGCTTCCCCCCAGTCCTGCCCTCC >In-frame_ENST00000264818_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(amino acids)=1034AA_start in transcript=0_stop in transcript=3104 MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESSLTAEEVCIHIAHKVGITPPCFNLFALFDAQAQVWLPPNHI LEIPRDASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDQTAQGMQLLDPASFEYLFEQGKHEFVNDVASLWELSTEEEIHHFK NESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFRRFLRDFQPGRLSQQMVMVKYLATLERLAPRF GTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPVEEEVNKEEGSSGSSGRNPQASLFGKKAKAHK AVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDG IHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRA GDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPG RDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLAS ALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFD GEAPLQSRSPSEGPSPSLRDACSLPWDVGSTGTAPPGDGYVQADARGPPDHEEHLYVNTQGLDAPEPEDSPKKDLFDMRPFEDALKLHEC SVAAGVTAAPLPLEDQWPSPPTRRAPVAPTEEQLRQEPWYHGRMSRRAAERMLRADGDFLVRDSVTNPGQYVLTGMHAGQPKHLLLVDPE -------------------------------------------------------------- >In-frame_ENST00000524462_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(transcript)=3441nt_BP=2057nt AGCTACCCGCGGGAGCGGGGAGGGGTCCGGGTTCGAGCTTGTGTTCCCCCGGAAGGGGCAAGCATGAGTTTGTGAATGACGTGGCATCAC TGTGGGAGCTGTCGACCGAGGAGGAGATCCACCACTTTAAGAATGAGAGCCTGGGCATGGCCTTTCTGCACCTCTGTCACCTCGCTCTCC GCCATGGCATCCCCCTGGAGGAGGTGGCCAAGAAGACCAGCTTCAAGGACTGCATCCCGCGCTCCTTCCGCCGGCATATCCGGCAGCACA GCGCCCTGACCCGGCTGCGCCTTCGGAACGTCTTCCGCAGGTTCCTGCGGGACTTCCAGCCGGGCCGACTCTCCCAGCAGATGGTCATGG TCAAATACCTAGCCACACTCGAGCGGCTGGCACCCCGCTTCGGCACAGAGCGTGTGCCCGTGTGCCACCTGAGGCTGCTGGCCCAGGCCG AGGGGGAGCCCTGCTACATCCGGGACAGTGGGGTGGCCCCTACAGACCCTGGCCCTGAGTCTGCTGCTGGGCCCCCAACCCACGAGGTGC TGGTGACAGGCACTGGTGGCATCCAGTGGTGGCCAGTAGAGGAGGAGGTGAACAAGGAGGAGGGTTCTAGTGGCAGCAGTGGCAGGAACC CCCAAGCCAGCCTGTTTGGGAAGAAGGCCAAGGCTCACAAGGCAGTCGGCCAGCCGGCAGACAGGCCGCGGGAGCCACTGTGGGCCTACT TCTGTGACTTCCGGGACATCACCCACGTGGTGCTGAAAGAGCACTGTGTCAGCATCCACCGGCAGGACAACAAGTGCCTGGAGCTGAGCT TGCCTTCCCGGGCTGCGGCGCTGTCCTTCGTGTCGCTGGTGGACGGCTATTTCCGCCTGACGGCCGACTCCAGCCACTACCTGTGCCACG AGGTGGCTCCCCCACGGCTGGTGATGAGCATCCGGGATGGGATCCACGGACCCCTGCTGGAGCCATTTGTGCAGGCCAAGCTGCGGCCCG AGGACGGCCTGTACCTCATTCACTGGAGCACCAGCCACCCCTACCGCCTGATCCTCACAGTGGCCCAGCGTAGCCAGGCACCAGACGGCA TGCAGAGCTTGCGGCTCCGAAAGTTCCCCATTGAGCAGCAGGACGGGGCCTTCGTGCTGGAGGGCTGGGGCCGGTCCTTCCCCAGCGTTC GGGAACTTGGGGCTGCCTTGCAGGGCTGCTTGCTGAGGGCCGGGGATGACTGCTTCTCTCTGCGTCGCTGTTGCCTGCCCCAACCAGGAG AAACCTCCAATCTCATCATCATGCGGGGGGCTCGGGCCAGCCCCAGGACACTCAACCTCAGCCAGCTCAGCTTCCACCGGGTTGACCAGA AGGAGATCACCCAGCTGTCCCACTTGGGCCAGGGCACAAGGACCAACGTGTATGAGGGCCGCCTGCGAGTGGAGGGCAGCGGGGACCCTG AGGAGGGCAAGATGGATGACGAGGACCCCCTCGTGCCTGGCAGGGACCGTGGGCAGGAGCTACGAGTGGTGCTCAAAGTGCTGGACCCTA GTCACCATGACATCGCCCTGGCCTTCTACGAGACAGCCAGCCTCATGAGCCAGGTCTCCCACACGCACCTGGCCTTCGTGCATGGCGTCT GTGTGCGCGGCCCTGAAAATATCATGGTGACAGAGTACGTGGAGCACGGACCCCTGGATGTGTGGCTGCGGAGGGAGCGGGGCCATGTGC CCATGGCTTGGAAGATGGTGGTGGCCCAGCAGCTGGCCAGCGCCCTCAGCTACCTGGAGAACAAGAACCTGGTTCATGGTAATGTGTGTG GCCGGAACATCCTGCTGGCCCGGCTGGGGTTGGCAGAGGGCACCAGCCCCTTCATCAAGCTGAGTGATCCTGGCGTGGGCCTGGGCGCCC TCTCCAGGGAGGAGCGGGTGGAGAGGATCCCCTGGCTGGCCCCCGAATGCCTACCAGGTGGGGCCAACAGCCTAAGCACCGCCATGGACA AGTGGGGGTTTGGCGCCACCCTCCTGGAGATCTGCTTTGACGGAGAGGCCCCTCTGCAGAGCCGCAGTCCCTCCGAGGGCCCATCTCCTT CTCTAAGAGATGCCTGCAGCCTGCCATGGGACGTGGGGTCCACCGGTACAGCTCCACCGGGGGACGGCTACGTGCAGGCGGACGCCCGGG GCCCCCCGGACCACGAGGAGCACCTGTATGTCAACACCCAGGGTCTGGACGCCCCCGAGCCGGAGGACAGCCCCAAAAAGGATCTGTTTG ACATGCGACCCTTTGAGGATGCCCTGAAGTTGCATGAGTGCTCAGTGGCGGCAGGCGTGACAGCAGCCCCTCTTCCCTTGGAGGACCAGT GGCCCAGCCCCCCTACCCGCCGGGCCCCTGTGGCCCCCACGGAGGAACAGCTGCGTCAGGAGCCCTGGTACCACGGCCGGATGAGCCGCC GGGCGGCAGAGAGGATGCTTCGAGCTGACGGGGACTTCCTTGTGCGAGACAGCGTCACCAACCCCGGGCAGTATGTCCTCACCGGCATGC ACGCCGGGCAGCCCAAGCACCTGCTGCTCGTGGACCCCGAGGGCGTGGTACGGACGAAGGACGTGCTGTTTGAGAGCATCAGCCACCTGA TCGACCACCACCTGCAGAACGGGCAGCCCATCGTGGCCGCCGAGAGTGAGCTGCACCTGCGTGGCGTGGTCTCACGGGAGCCCTGAGCCA GGTGACCGTTCTCAGCCCTGGCTCCTGCCTGTTCTCAGCCCCGGCTCCTGCCTGTCATGGCCTTGGGGCTCTCAGCCCTCCTCCTGGATC CTGGTCAGGCCGAACCACCGCTGCCTCTCCTTCCTCCGCATGAGCCTCTGGCATGGTCCTTCCTCCAGCTGGCCCCGGGCTGGGCAGAGC CTCCTCCTGCCGGGGCCCCTGCCCACCCCCTCCTTTGCCTGGAGTGAGGGTGTTCATACCAAAGACGGAACCATTTCGCCTTTAAAGAAA ATATATCCAGAAGCAGCCGCTGCCTCGGAGCCCTGGCCCTTGGGTCCCCCTCTCGCCTGGCTGGTTCGGTCTAACGCCCCGGAGAGTCAG GGCTCCCAGGACCCTGGGGAGGAGGCGGATTCCGGGCCTGGCTGGGCTTCCTCTTCCCACCTGAGGACTGGGTGCACAGTTGTCTTTGAG GGGGGACGCTTAAGGTGCTTTGGGGTTCTCAGGCCAGGATACATGCTGGCGCTGAAGTGCAGGCAGCCTTGAGGTCACCTGGGATCTCGG GGTAGCCAGGCTGCTCCAAGACAGTGGATATCGAGGCAGTCGTGAGGCCCCTACTCCACCTGGGAGCAGGGGAAGGACGTGGTTGCCTGG CCTGGGCTGCGCCCAGCAGCTTCCCCCCAGTCCTGCCCTCCCAGCTGTCGACCCAGATGGGATGTTCGGATCGGTTTGTAATTAAACCTG >In-frame_ENST00000524462_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(amino acids)=885AA_start in transcript=38_stop in transcript=2695 MCSPGRGKHEFVNDVASLWELSTEEEIHHFKNESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFR RFLRDFQPGRLSQQMVMVKYLATLERLAPRFGTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPV EEEVNKEEGSSGSSGRNPQASLFGKKAKAHKAVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSL VDGYFRLTADSSHYLCHEVAPPRLVMSIRDGIHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQ QDGAFVLEGWGRSFPSVRELGAALQGCLLRAGDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGT RTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEY VEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWL APECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEGPSPSLRDACSLPWDVGSTGTAPPGDGYVQADARGPPDHEEHLYVNT QGLDAPEPEDSPKKDLFDMRPFEDALKLHECSVAAGVTAAPLPLEDQWPSPPTRRAPVAPTEEQLRQEPWYHGRMSRRAAERMLRADGDF -------------------------------------------------------------- >In-frame_ENST00000525621_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(transcript)=4332nt_BP=2948nt AAAAAAAAAAAAATCCAATGGTGACGAGCAGGGAGAACAGAGCAGCTGCCAATGGGCGTGTGCGTTTCAGGCGGCCAATGGGAGGAGGCG TCTCGGCGGGGGACAAGCAGTAGCTACCCGCGGGAGCGGGGAGGGGTCCGGGTTCGAGCTTGTGTTCCCCCGGAAGGGTGAGTCTGGACG CGGGCGCGGAAGGAGCGCGGCCGGAGGTCCTCAGGAAGAAGCCGCGGGGACTGGCTGCGCTTGACAGGCTGCACTTGGATGGGAGCACCT GGTGCCTCGGGACTGCTCCGATGCCCGGGTCTGTGCTGAATGTGTAATATGCGGAACTATATTGAAACATTACAACCATCTTTTGATGGC AACACCCTGAGGACCTCCCTTTTCCAGATGGGGAAACTGAGGCCCAGAATTGCTAAGTGGCTTGCTTGAGTTGACACAGGGAGCTCCAGG ACTCACCCTCAGCTGAGCCACCTGCCGGGAGCATGCCTCTGCGCCACTGGGGGATGGCCAGGGGCAGTAAGCCCGTTGGGGATGGAGCCC AGCCCATGGCTGCCATGGGAGGCCTGAAGGTGCTTCTGCACTGGGCTGGTCCAGGCGGCGGGGAGCCCTGGGTCACTTTCAGTGAGTCAT CGCTGACAGCTGAGGAAGTCTGCATCCACATTGCACATAAAGTTGGTATCACTCCTCCTTGCTTCAATCTCTTTGCCCTCTTCGATGCTC AGGCCCAAGTCTGGTTGCCCCCAAACCACATCCTAGAGATCCCCAGAGATGCAAGCCTGATGCTATATTTCCGCATAAGGTTTTATTTCC GGAACTGGCATGGCATGAATCCTCGGGAACCGGCTGTGTACCGTTGTGGGCCCCCAGGAACCGAGGCATCCTCAGATCAGACAGCACAGG GGATGCAACTCCTGGACCCAGCCTCATTTGAGTACCTCTTTGAGCAGGGCAAGCATGAGTTTGTGAATGACGTGGCATCACTGTGGGAGC TGTCGACCGAGGAGGAGATCCACCACTTTAAGAATGAGAGCCTGGGCATGGCCTTTCTGCACCTCTGTCACCTCGCTCTCCGCCATGGCA TCCCCCTGGAGGAGGTGGCCAAGAAGACCAGCTTCAAGGACTGCATCCCGCGCTCCTTCCGCCGGCATATCCGGCAGCACAGCGCCCTGA CCCGGCTGCGCCTTCGGAACGTCTTCCGCAGGTTCCTGCGGGACTTCCAGCCGGGCCGACTCTCCCAGCAGATGGTCATGGTCAAATACC TAGCCACACTCGAGCGGCTGGCACCCCGCTTCGGCACAGAGCGTGTGCCCGTGTGCCACCTGAGGCTGCTGGCCCAGGCCGAGGGGGAGC CCTGCTACATCCGGGACAGTGGGGTGGCCCCTACAGACCCTGGCCCTGAGTCTGCTGCTGGGCCCCCAACCCACGAGGTGCTGGTGACAG GCACTGGTGGCATCCAGTGGTGGCCAGTAGAGGAGGAGGTGAACAAGGAGGAGGGTTCTAGTGGCAGCAGTGGCAGGAACCCCCAAGCCA GCCTGTTTGGGAAGAAGGCCAAGGCTCACAAGGCAGTCGGCCAGCCGGCAGACAGGCCGCGGGAGCCACTGTGGGCCTACTTCTGTGACT TCCGGGACATCACCCACGTGGTGCTGAAAGAGCACTGTGTCAGCATCCACCGGCAGGACAACAAGTGCCTGGAGCTGAGCTTGCCTTCCC GGGCTGCGGCGCTGTCCTTCGTGTCGCTGGTGGACGGCTATTTCCGCCTGACGGCCGACTCCAGCCACTACCTGTGCCACGAGGTGGCTC CCCCACGGCTGGTGATGAGCATCCGGGATGGGATCCACGGACCCCTGCTGGAGCCATTTGTGCAGGCCAAGCTGCGGCCCGAGGACGGCC TGTACCTCATTCACTGGAGCACCAGCCACCCCTACCGCCTGATCCTCACAGTGGCCCAGCGTAGCCAGGCACCAGACGGCATGCAGAGCT TGCGGCTCCGAAAGTTCCCCATTGAGCAGCAGGACGGGGCCTTCGTGCTGGAGGGCTGGGGCCGGTCCTTCCCCAGCGTTCGGGAACTTG GGGCTGCCTTGCAGGGCTGCTTGCTGAGGGCCGGGGATGACTGCTTCTCTCTGCGTCGCTGTTGCCTGCCCCAACCAGGAGAAACCTCCA ATCTCATCATCATGCGGGGGGCTCGGGCCAGCCCCAGGACACTCAACCTCAGCCAGCTCAGCTTCCACCGGGTTGACCAGAAGGAGATCA CCCAGCTGTCCCACTTGGGCCAGGGCACAAGGACCAACGTGTATGAGGGCCGCCTGCGAGTGGAGGGCAGCGGGGACCCTGAGGAGGGCA AGATGGATGACGAGGACCCCCTCGTGCCTGGCAGGGACCGTGGGCAGGAGCTACGAGTGGTGCTCAAAGTGCTGGACCCTAGTCACCATG ACATCGCCCTGGCCTTCTACGAGACAGCCAGCCTCATGAGCCAGGTCTCCCACACGCACCTGGCCTTCGTGCATGGCGTCTGTGTGCGCG GCCCTGAAAATATCATGGTGACAGAGTACGTGGAGCACGGACCCCTGGATGTGTGGCTGCGGAGGGAGCGGGGCCATGTGCCCATGGCTT GGAAGATGGTGGTGGCCCAGCAGCTGGCCAGCGCCCTCAGCTACCTGGAGAACAAGAACCTGGTTCATGGTAATGTGTGTGGCCGGAACA TCCTGCTGGCCCGGCTGGGGTTGGCAGAGGGCACCAGCCCCTTCATCAAGCTGAGTGATCCTGGCGTGGGCCTGGGCGCCCTCTCCAGGG AGGAGCGGGTGGAGAGGATCCCCTGGCTGGCCCCCGAATGCCTACCAGGTGGGGCCAACAGCCTAAGCACCGCCATGGACAAGTGGGGGT TTGGCGCCACCCTCCTGGAGATCTGCTTTGACGGAGAGGCCCCTCTGCAGAGCCGCAGTCCCTCCGAGGGCCCATCTCCTTCTCTAAGAG ATGCCTGCAGCCTGCCATGGGACGTGGGGTCCACCGGTACAGCTCCACCGGGGGACGGCTACGTGCAGGCGGACGCCCGGGGCCCCCCGG ACCACGAGGAGCACCTGTATGTCAACACCCAGGGTCTGGACGCCCCCGAGCCGGAGGACAGCCCCAAAAAGGATCTGTTTGACATGCGAC CCTTTGAGGATGCCCTGAAGTTGCATGAGTGCTCAGTGGCGGCAGGCGTGACAGCAGCCCCTCTTCCCTTGGAGGACCAGTGGCCCAGCC CCCCTACCCGCCGGGCCCCTGTGGCCCCCACGGAGGAACAGCTGCGTCAGGAGCCCTGGTACCACGGCCGGATGAGCCGCCGGGCGGCAG AGAGGATGCTTCGAGCTGACGGGGACTTCCTTGTGCGAGACAGCGTCACCAACCCCGGGCAGTATGTCCTCACCGGCATGCACGCCGGGC AGCCCAAGCACCTGCTGCTCGTGGACCCCGAGGGCGTGGTACGGACGAAGGACGTGCTGTTTGAGAGCATCAGCCACCTGATCGACCACC ACCTGCAGAACGGGCAGCCCATCGTGGCCGCCGAGAGTGAGCTGCACCTGCGTGGCGTGGTCTCACGGGAGCCCTGAGCCAGGTGACCGT TCTCAGCCCTGGCTCCTGCCTGTTCTCAGCCCCGGCTCCTGCCTGTCATGGCCTTGGGGCTCTCAGCCCTCCTCCTGGATCCTGGTCAGG CCGAACCACCGCTGCCTCTCCTTCCTCCGCATGAGCCTCTGGCATGGTCCTTCCTCCAGCTGGCCCCGGGCTGGGCAGAGCCTCCTCCTG CCGGGGCCCCTGCCCACCCCCTCCTTTGCCTGGAGTGAGGGTGTTCATACCAAAGACGGAACCATTTCGCCTTTAAAGAAAATATATCCA GAAGCAGCCGCTGCCTCGGAGCCCTGGCCCTTGGGTCCCCCTCTCGCCTGGCTGGTTCGGTCTAACGCCCCGGAGAGTCAGGGCTCCCAG GACCCTGGGGAGGAGGCGGATTCCGGGCCTGGCTGGGCTTCCTCTTCCCACCTGAGGACTGGGTGCACAGTTGTCTTTGAGGGGGGACGC TTAAGGTGCTTTGGGGTTCTCAGGCCAGGATACATGCTGGCGCTGAAGTGCAGGCAGCCTTGAGGTCACCTGGGATCTCGGGGTAGCCAG GCTGCTCCAAGACAGTGGATATCGAGGCAGTCGTGAGGCCCCTACTCCACCTGGGAGCAGGGGAAGGACGTGGTTGCCTGGCCTGGGCTG CGCCCAGCAGCTTCCCCCCAGTCCTGCCCTCCCAGCTGTCGACCCAGATGGGATGTTCGGATCGGTTTGTAATTAAACCTGGGAATGGCC >In-frame_ENST00000525621_ENST00000264554_TCGA-BH-A0BP-01A_TYK2_chr19_10468440_-_SHC2_chr19_430747_length(amino acids)=1034AA_start in transcript=482_stop in transcript=3586 MPLRHWGMARGSKPVGDGAQPMAAMGGLKVLLHWAGPGGGEPWVTFSESSLTAEEVCIHIAHKVGITPPCFNLFALFDAQAQVWLPPNHI LEIPRDASLMLYFRIRFYFRNWHGMNPREPAVYRCGPPGTEASSDQTAQGMQLLDPASFEYLFEQGKHEFVNDVASLWELSTEEEIHHFK NESLGMAFLHLCHLALRHGIPLEEVAKKTSFKDCIPRSFRRHIRQHSALTRLRLRNVFRRFLRDFQPGRLSQQMVMVKYLATLERLAPRF GTERVPVCHLRLLAQAEGEPCYIRDSGVAPTDPGPESAAGPPTHEVLVTGTGGIQWWPVEEEVNKEEGSSGSSGRNPQASLFGKKAKAHK AVGQPADRPREPLWAYFCDFRDITHVVLKEHCVSIHRQDNKCLELSLPSRAAALSFVSLVDGYFRLTADSSHYLCHEVAPPRLVMSIRDG IHGPLLEPFVQAKLRPEDGLYLIHWSTSHPYRLILTVAQRSQAPDGMQSLRLRKFPIEQQDGAFVLEGWGRSFPSVRELGAALQGCLLRA GDDCFSLRRCCLPQPGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPG RDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLAS ALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFD GEAPLQSRSPSEGPSPSLRDACSLPWDVGSTGTAPPGDGYVQADARGPPDHEEHLYVNTQGLDAPEPEDSPKKDLFDMRPFEDALKLHEC SVAAGVTAAPLPLEDQWPSPPTRRAPVAPTEEQLRQEPWYHGRMSRRAAERMLRADGDFLVRDSVTNPGQYVLTGMHAGQPKHLLLVDPE -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for TYK2-SHC2 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for TYK2-SHC2 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for TYK2-SHC2 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | TYK2 | C1969086 | Tyrosine Kinase 2 Deficiency | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET |
| Hgene | TYK2 | C0003873 | Rheumatoid Arthritis | 2 | CTD_human |
| Hgene | TYK2 | C0008312 | Primary biliary cirrhosis | 1 | CTD_human |
| Hgene | TYK2 | C0009171 | Cocaine Abuse | 1 | CTD_human |
| Hgene | TYK2 | C0010346 | Crohn Disease | 1 | CTD_human;GENOMICS_ENGLAND |
| Hgene | TYK2 | C0011854 | Diabetes Mellitus, Insulin-Dependent | 1 | CTD_human |
| Hgene | TYK2 | C0023892 | Biliary cirrhosis | 1 | CTD_human |
| Hgene | TYK2 | C0026769 | Multiple Sclerosis | 1 | CTD_human |
| Hgene | TYK2 | C0030246 | Pustulosis of Palms and Soles | 1 | CTD_human |
| Hgene | TYK2 | C0033860 | Psoriasis | 1 | CTD_human |
| Hgene | TYK2 | C0041696 | Unipolar Depression | 1 | PSYGENET |
| Hgene | TYK2 | C0156147 | Crohn's disease of large bowel | 1 | CTD_human |
| Hgene | TYK2 | C0205734 | Diabetes, Autoimmune | 1 | CTD_human |
| Hgene | TYK2 | C0206182 | Lymphomatoid Papulosis | 1 | ORPHANET |
| Hgene | TYK2 | C0236736 | Cocaine-Related Disorders | 1 | CTD_human |
| Hgene | TYK2 | C0238065 | Secondary Biliary Cholangitis | 1 | CTD_human |
| Hgene | TYK2 | C0267380 | Crohn's disease of the ileum | 1 | CTD_human |
| Hgene | TYK2 | C0342302 | Brittle diabetes | 1 | CTD_human |
| Hgene | TYK2 | C0344315 | Depressed mood | 1 | PSYGENET |
| Hgene | TYK2 | C0600427 | Cocaine Dependence | 1 | CTD_human |
| Hgene | TYK2 | C0678202 | Regional enteritis | 1 | CTD_human |
| Hgene | TYK2 | C0751324 | Multiple Sclerosis, Acute Fulminating | 1 | CTD_human |
| Hgene | TYK2 | C0949272 | IIeocolitis | 1 | CTD_human |
| Hgene | TYK2 | C1269683 | Major Depressive Disorder | 1 | PSYGENET |
| Hgene | TYK2 | C1301362 | Primary Cutaneous Anaplastic Large Cell Lymphoma | 1 | ORPHANET |
| Hgene | TYK2 | C1456784 | Paranoia | 1 | CTD_human |
| Hgene | TYK2 | C1961099 | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | CTD_human |
| Hgene | TYK2 | C3837958 | Diabetes Mellitus, Ketosis-Prone | 1 | CTD_human |
| Hgene | TYK2 | C4551595 | Biliary Cirrhosis, Primary, 1 | 1 | CTD_human |
| Hgene | TYK2 | C4554117 | Diabetes Mellitus, Sudden-Onset | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies